Lupin Expands European Footprint with VISUfarma Acquisition

Lupin Ltd. announced on Thursday its acquisition of VISUfarma B.V., a European pharmaceutical company specializing in ophthalmology. The deal marks a "significant milestone" in Lupin's strategic agenda to broaden its specialty care offerings and enhance its footprint in the European market.

With this integration, Lupin's ophthalmology portfolio now boasts over 60 branded products, covering a range of eye health needs from dry eye and glaucoma to retinal health and specialty nutraceuticals. The company projects that this acquisition will bolster its capacity to satisfy the rising global demand for innovative eye care, fueled by an aging population and increased diabetes-related eye issues.

Chief Executive Officer Vinita Gupta expressed enthusiasm about the acquisition, highlighting its immediate positive impact and strategic value in solidifying Lupin's European presence. Paolo Ciocetti, CEO of VISUfarma Italy, echoed this sentiment, optimistic about the partnership's potential to revolutionize eye care solutions throughout Europe and beyond.